Gastric Carcinoma Staging
Gastric carcinoma is staged using the American Joint Committee on Cancer (AJCC) 8th edition TNM classification system, which categorizes disease based on tumor depth (T), lymph node involvement (N), and distant metastasis (M). 1
TNM Classification Components
T Category (Tumor Depth)
The T category describes the depth of tumor invasion through the gastric wall:
- Tis: Carcinoma in situ (intraepithelial tumor without invasion)
- T1: Tumor invades lamina propria or submucosa
- T1a: Lamina propria or muscularis mucosae
- T1b: Submucosa
- T2: Tumor invades muscularis propria
- T3: Tumor penetrates subserosal connective tissue without invading visceral peritoneum or adjacent structures
- T4: Tumor invades serosa or adjacent structures
- T4a: Tumor invades serosa (visceral peritoneum)
- T4b: Tumor invades adjacent structures
N Category (Lymph Node Involvement)
The N category is based on the number of regional lymph nodes containing metastatic disease:
- N0: No regional lymph node metastasis
- N1: Metastasis in 1-2 regional lymph nodes
- N2: Metastasis in 3-6 regional lymph nodes
- N3: Metastasis in 7 or more regional lymph nodes
- N3a: Metastasis in 7-15 regional lymph nodes
- N3b: Metastasis in 16 or more regional lymph nodes
M Category (Distant Metastasis)
- M0: No distant metastasis
- M1: Distant metastasis present
Stage Groupings (AJCC 8th Edition)
The TNM components are combined to determine overall stage, which correlates with prognosis 2:
- Stage 0: Tis N0 M0
- Stage IA: T1 N0 M0
- Stage IB: T1 N1 M0 or T2 N0 M0
- Stage IIA: T1 N2 M0, T2 N1 M0, or T3 N0 M0
- Stage IIB: T1 N3a M0, T2 N2 M0, T3 N1 M0, or T4a N0 M0
- Stage IIIA: T2 N3a M0, T3 N2 M0, T4a N1 M0, or T4b N0 M0
- Stage IIIB: T1 N3b M0, T2 N3b M0, T3 N3a M0, T4a N2 M0, T4a N3a M0, or T4b N1-2 M0
- Stage IIIC: T3 N3b M0, T4a N3b M0, or T4b N3a-3b M0
- Stage IV: Any T, Any N, M1
Prognostic Significance
The 8th edition demonstrates superior prognostic stratification compared to the 7th edition, with distinct 5-year survival rates for each stage 2:
- Stage IA: ~95%
- Stage IB: ~89-94%
- Stage IIA: ~80-85%
- Stage IIB: ~67-71%
- Stage IIIA: ~54-68%
- Stage IIIB: ~38-48%
- Stage IIIC: ~21-23%
- Stage IV: ~13-18%
Important Clinical Considerations
Anatomic Location and Classification
Tumors with their midpoint in the proximal 2 cm of the stomach that cross the esophagogastric junction (EGJ) are staged as esophageal carcinomas, while those with epicenter >2 cm into the proximal stomach are staged as gastric carcinomas 1. This distinction is critical for proper staging and treatment planning.
Pathologic Requirements
For accurate staging, pathology reports must include 1:
- Depth of tumor invasion (T category)
- Number of lymph nodes examined and number positive (N category)
- Presence of vascular/lymphatic invasion
- Margin status
- Histologic type and grade
- MSI/MMR status (universal testing recommended)
Staging Modalities
CT scanning is the primary imaging modality for preoperative staging 1, though endoscopic ultrasound (EUS) can be useful for differentiating early versus locally advanced disease, particularly for identifying superficial tumors amenable to endoscopic resection 1.
Common Pitfall
The accuracy of EUS is operator-dependent and ranges from 46-88% for T staging and 31-90% for N staging 1. Therefore, EUS should be used in combination with other staging modalities rather than as a standalone tool, particularly when determining if early-stage disease is present.